VanEck Medical Robotics and Bionic Engineering UCITS ETF

PhysicalIndex replication
AccumulatingDistribution policy
0.55 %TER
£11.87M Fund size
24Number of positions
— TD
72.32 %Top 10 share
USDCurrency
5SRI

Current price

£15.24
19 Nov 2026
1D
1W
1M
3M
6M
1Y
3Y
Max

Description

The Fund’s investment objective is to replicate, before fees and expenses, the MVIS® Global Bionic Healthcare ESG Index (the “Index”). In order to seek to achieve its investment objective, the Manager will normally use a replication strategy by investing directly in the underlying equity securities of the Index being stock, American depository receipts (ADRs), and global depository receipts (GDRs) that consists of the component securities of the Index. Such equity securities which form part of the Index are required to be issued by companies who generate at least 50% (25% for current components) of their revenues from medical, dental or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue. This does not include companies involved in implantable or wearable devices or materials used only for cosmetic purposes. Such equity securities must be listed or traded on the Markets referred to in Appendix II of the Prospectus. The Manager has categorised the Product as meeting the provisions set out in Article 9(1) of Regulation (EU) 2019/2088 on sustainability related disclosures in the financial services sector ("SFDR") for products, which have sustainable investment as their objective and where an index has been designated as a reference benchmark. The Index considers ESG factors as further detailed in the Index methodology available on the Index Provider’s website and in the Prospectus. Where it is not practical or cost efficient for the Fund to fully replicate the Index, the Manager may utilise an optimised sampling methodology. The Fund may also (or alternatively) invest in financial derivative instruments (FDIs) which relate to the Index or constituents of the Index. The Fund may invest up to 15% of its Net Asset Value directly in shares issued by companies listed on the Shanghai Stock Exchange or the Shenzhen Stock Exchange. The Fund may invest more than 20% of its Net Asset Value in emerging markets. The FDIs which the Fund may use are futures, options (puts and calls), swaps (including equity swaps and swaps on the Index), currency forwards and nondeliverable forwards (a forward contract that does not require settlement on maturity) (NDFs). The Fund may also invest in ancillary liquid assets and money market instruments which may include bank deposits, depositary receipts, certificates of deposit, fixed or floating rate instruments (treasury bills), commercial paper, floating rate notes and freely transferable promissory notes. The ancillary liquid assets, money market instruments and FDI (other than permitted unlisted investments) will be listed or traded on the Markets referred to in Appendix II of the Prospectus. The Fund may not invest more than 10% of its Net Asset Value in open-ended collective investment. Furthermore, the Fund may not invest less than 51% of its Net Asset Value in equity securities which constitute "equity participation" within the meaning of section 2, Article 8 of the German Investment Tax Act. The Fund, using a “passive” or indexing investment approach, attempts to approximate the investment performance of the Index by investing in a portfolio of securities that generally replicates the Index. The Investment Manager will regularly monitor the Fund’s tracking accuracy. Recommendation: This Fund may not be appropriate for investors who plan to withdraw their money within 5 years. Fund’s base currency: U.S. Dollar Distribution policy: Income accumulated The shares are admitted for trading on various stock exchanges and can be traded on the secondary market. The price of the shares offered on the secondary market may deviate from the net asset value of the shares. The return of the Fund is directly related to the return of the underlying assets minus the costs associated with the Fund. If the performance of the underlying assets decreases, the performance of the Fund will also decrease. There is no capital protection against Market Risk.

Return

Here you can see the performance (incl. distributions) of the VanEck Medical Robotics and Bionic Engineering UCITS ETF.

Period Perfor­mance
1 Week-1.07 %
1 Month+6.05 %
3 Months+3.88 %
6 Months+15.64 %
1 Year-3.98 %
3 Years+4.99 %(1.64 % p.a.)
5 Years—
10 Years—
Since inception -7.61 %(-1.98 % p.a.)
Year Perfor­mance
YTD-1.25 %
2025-10.63 %
2024+5.76 %
2023+1.06 %
2022—
2021—
As of: 19 Nov 2026. Performance displayed in GBP

Master data

Key master data for the VanEck Medical Robotics and Bionic Engineering UCITS ETF

Total expense ratio (TER) 0.55 %
Index replication Physical
Replication method Full
Distribution policy Accumulating
Fund size £11.87M
Fund launch 2 Dec 2022
Fund currency USD
Currency hedging No 
Fund domicileIrland
Risk indicator (SRI)
5 · medium-high risk class

Risk metrics

Key risk and analysis metrics for the VanEck Medical Robotics and Bionic Engineering UCITS ETF

Volatility
17.25 % 1 Year
18.20 % 3 Years
— 5 Years
max. Drawdown
-19.34 % 1 Year
-20.98 % 3 Years
— 5 Years
Sharpe Ratio
-0.38 1 Year
0.15 3 Years
— 5 Years
XLM
85.32

Information about the MVIS Global Bionic Healthcare ESG NR USD Index

Index name MVIS Global Bionic Healthcare ESG NR USD (1)
Included securities 32
Stock positions 24
Bond positions 0
Cash and other positions 8

More ETFs tracking the MVIS Global Bionic Healthcare ESG NR USD Index

Here you can find alternative index funds for the MVIS Global Bionic Healthcare ESG NR USD.

Fund nameWKNTER
No results

Frequently asked questions

Here you will find all answers to your questions about the VanEck Medical Robotics and Bionic Engineering UCITS ETF

Master data is provided by Morningstar (stocks, ETFs, funds), CoinGecko (cryptocurrencies) and Isarvest GmbH. Price data is at least 15-minute delayed exchange prices (stocks, ETFs, funds) or NAV prices (ETFs, funds). Real-time prices – where available – are provided by the providers and Lang & Schwarz (stocks, ETFs, funds) and CoinGecko (cryptocurrencies).

Isarvest GmbH assumes no liability for the information presented and cannot guarantee that the data is complete and accurate.

Affiliate notice *
Links marked with an asterisk (*) are advertising or affiliate links. If you purchase or sign up through this link, we receive compensation from the provider. This comes at no additional cost or disadvantage to you. We use this revenue to fund our free services. Thank you for your support.